Acasti Pharma to Present at Q4 Investor Summit
10 11월 2022 - 6:15AM
Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and
TSX-V: ACST), a late-stage, specialty pharma company advancing
three clinical stage drug candidates addressing rare and orphan
diseases, today announced that Jan D’Alvise, President and CEO of
Acasti Pharma will be presenting virtually at the Q4 Investor
Summit. The Company will be conducting a webcasted presentation and
participating in one-on-one meetings with investors.
Event: Q4 Investor
SummitPresentation: November 15th at 1:00 PM
ETLocation: VirtualWebcast:
https://us06web.zoom.us/webinar/register/WN_UYpn3XzeQxaos12x-HK0Sg
Investors interested in participating in
one-on-one meetings should contact Acasti Investor Relations at
ACST@lythampartners.com, or their Investor Summit
representatives.
About AcastiAcasti is a
specialty pharma company advancing three clinical stage drug
candidates addressing rare and orphan diseases. Acasti’s novel drug
candidates have the potential to improve the performance of
currently marketed drugs by achieving faster onset of action,
enhanced efficacy, reduced side effects, and more convenient drug
delivery—all which could help to increase treatment compliance and
improve patient outcomes.
Acasti’s three lead clinical assets have each
been granted Orphan Drug Designation by the FDA, which provides the
assets with seven years of marketing exclusivity post-launch in the
United States, and have additional intellectual property protection
with over 40 granted and pending patents. Acasti’s lead clinical
assets target underserved orphan diseases: (i) GTX-104, an
intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a
rare and life-threatening medical emergency in which bleeding
occurs over the surface of the brain in the subarachnoid space
between the brain and skull; (ii) GTX-102, an oral mucosal spray
targeting Ataxia-telangiectasia (A-T), a progressive,
neurodegenerative genetic disease that primarily affects children,
causing severe disability, and for which no treatment currently
exists; and (iii) GTX-101, a topical spray targeting Postherpetic
Neuralgia (PHN), a persistent and often debilitating neuropathic
pain caused by nerve damage from the varicella zoster virus
(shingles), which may persist for months and even years. For more
information, please
visit: https://www.acastipharma.com/en.
Forward-Looking Statements
Statements in this press release that are not statements of
historical or current fact constitute “forward-looking information”
within the meaning of Canadian securities laws and “forward-looking
statements” within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995, as amended, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (collectively,
“forward- looking statements”). Such forward looking statements
involve known and unknown risks, uncertainties, and other unknown
factors that could cause the actual results of Acasti to be
materially different from historical results or from any future
results expressed or implied by such forward-looking statements. In
addition to statements which explicitly describe such risks and
uncertainties, readers are urged to consider statements labelled
with the terms “believes,” “belief,” “expects,” “intends,”
“anticipates,” “estimates,” “potential,” “should,” “may,” “will,”
“plans,” “continue”, “targeted” or other similar expressions to be
uncertain and forward- looking. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release.
These forward-looking statements are based upon Acasti’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, including, without limitation: (i) the success and
timing of regulatory submissions of the planned Phase 3 safety
study for GTX-104 and Acasti’s other pre-clinical and clinical
trials; (ii) regulatory requirements or developments and the
outcome of meetings with the FDA; (iii) changes to clinical trial
designs and regulatory pathways; (iv) legislative, regulatory,
political and economic developments; and (v) costs associated with
Acasti’s clinical trials. The foregoing review of important factors
that could cause actual events to differ from expectations should
not be construed as exhaustive and should be read in conjunction
with statements that are included herein and elsewhere, including
the risk factors detailed in documents that have been and may be
filed by Acasti from time to time with the SEC. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Acasti undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
Neither NASDAQ, the TSXV nor its Regulation Services Provider
(as that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Acasti Contact:
Jan D’AlviseChief Executive OfficerTel:
450-686-4555Email:info@acastipharma.com www.acastipharma.com
Investor Relations:Robert BlumLytham Partners,
LLC602-889-9700ACST@lythampartners.com
Acasti Pharma (TSXV:ACST)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Acasti Pharma (TSXV:ACST)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024